Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
ApexOnco Front Page
Recent articles
6 November 2024
The company abandons TNG908, but is still all in on the troubled target.
31 October 2024
The group goes after a KRAS-related target on which Boehringer recently gave up.
29 October 2024
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
28 October 2024
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
25 October 2024
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
25 October 2024
The company reckons it’s got what it takes to hit the right member of the FGFR family.
25 October 2024
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
Recent Quick take
- 23 October 2024
- 22 October 2024
- 22 October 2024
- 21 October 2024
- 21 October 2024
- 18 October 2024
- 18 October 2024
- 18 October 2024
- 16 October 2024
- 15 October 2024